MYC and pancreatic neoplasm: Thus, our data suggest that FBP1 promotes c-Myc degradation through the inhibition of the ERK pathway in pancreatic cancer cells, and the BET inhibitor downregulates c-Myc partially via stabilizing FBP1 in pancreatic cancer cells.